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Introduction
Citrobacter braakii (C. braakii) is a genus of Gram-negative, straight, 
facultative anaerobic and motile bacilli bacterium widely distributed in 
water, soil, and food in the environment. It is also commonly found in 
urinary, intestinal, and respiratory tract of human and animals, belongs 
to Enterobacteriaceae family. It has been associated with various 
nosocomial and community acquired infections in humans [1]. Arens 
et al. reported about 11 genetically distinct species within the genus 
Citrobacter [2]. The main clinical manifestations have been reported 
due to nosocomial infections of Citrobacter species such as bacteremias 
[3], endocarditis [4], urinary tract infections [1], neonatal meningitis 
[5], pneumonia [6] and brain abscess [7]. Based on literature it has 
been demonstrated that 0.8% of Gram-negative infections caused by 
Citrobacter spp. [8]. In hospital settings, about 3-6% Citrobacter spp. 
causes nosocomial infection among all Enterobacteriaceae family 
[9]. Although it has low virulence property responsible for host cell 
invasion instead of it invade blood brain barrier (BBB) of human brain 
microvascular endothelial cells (HBMEC) and causes meningitis. 
Moreover, due to overproduction of chromosomal β-lactamase 
enzyme leads to antimicrobials resistance [10]. Aminoglycosides, 
fluoroquinolones, carbapenems, new oral cephems and many third and 
fourth-generation cephems, such as cefepime and cefpirome, are the 
drugs of choice to treat C. braakii associated infections but it possess 
high level of resistance against penicillin and other antibiotics [11,12]. 
Therefore, an alternative strategy is needed to alter the antimicrobial 
sensitivity profile against C. braakii strain. In recent years, biofield 
treatment was proved to be an alternative method which has impact on 
various properties of living and non-living materials in a cost effective 
manner. It is already demonstrated that energy can neither be created 
nor be destroyed but it can be transferred through various processes such 
as thermal, chemical, kinetic, nuclear, etc. [13-15]. Similarly, electrical 
current exists inside the human body in the form of vibratory energy 
particles like ions, protons, and electrons and they generate magnetic 
field in the human body [16,17]. Afterward, Harold Saxton Burr had 
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Abstract
Citrobacter braakii (C. braakii) is widespread in nature, mainly found in human urinary tract. The current study 
was attempted to investigate the effect of Mr. Trivedi’s biofield treatment on C. braakii in lyophilized as well as 
revived state for antimicrobial susceptibility pattern, biochemical characteristics, and biotype number. Lyophilized 
vial of ATCC strain of C. braakii was divided into two parts, Group (Gr.) I: control and Gr. II: treated. Gr. II was further 
subdivided into two parts, Gr. IIA and Gr. IIB. Gr. IIA was analysed on day 10 while Gr. IIB was stored and analysed 
on day 159 (Study I). After retreatment on day 159, the sample (Study II) was divided into three separate tubes. 
First, second and third tube was analysed on day 5, 10 and 15, respectively. All experimental parameters were 
studied using automated MicroScan Walk-Away® system. The 16S rDNA sequencing of lyophilized treated sample 
was carried out to correlate the phylogenetic relationship of C. braakii with other bacterial species. The antimicrobial 
susceptibility and minimum inhibitory concentration showed 39.29% and 15.63% alteration respectively in treated 
cells of C. braakii as compared to control. Tetracycline showed improved sensitivity pattern, i.e., from resistant to 
susceptible after biofield treatment, with support of decreased MIC value (>8 to ≤ 4 µg/mL) by two-fold in all the 
treated samples as compared to the control. Biochemical reactions also showed significant (42.42%) alteration in 
the treated samples with respect to the control. Biotype numbers with species were substantially changed in Gr. IIA 
(53131052, Citrobacter freundii complex) on day 10 and in Gr. IIB, Study I (53111052; Citrobacter amalonaticus) 
on day 159 as compared to the control (77365776; Citrobacter braakii). Moreover, biotype numbers with species 
were substantially changed in Gr. IIB, Study II after retreatment on day 5 (53111042, Citrobacter amalonaticus) and 
(53131052; Citrobacter freundii complex) on day 10 and 15 as compared to the control. 16S rDNA analysis showed 
that the identified microbe as Citrobacter freundii (GenBank Accession Number: DQ517285) with 95% identity. The 
nearest homolog genus-species of C. braakii was found to be Citrobacter werkmanii (Accession No. AF025373). The 
results suggested that biofield treatment has a significant impact on C. braakii in lyophilized as well as revived state. 
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performed the detailed studies on the correlation of electric current 
with physiological process and concluded that every single process in 
the human body had an electrical significance [18]. Recently, it was 
discovered that all electrical process happening in body have strong 
relationship with magnetic field as mentioned by Ampere’s law, which 
states that the moving charge produces magnetic fields in surrounding 
space [19,20]. Thus, the human body emits the electromagnetic waves 
in form of bio-photons, which surround the body and it is commonly 
known as biofield. Therefore, the biofield consists of electromagnetic 
field, being generated by moving electrically charged particles (ions, 
cell, molecule, etc.) inside the human body. According to Rivera-Ruiz 
et al., it was reported that electrocardiography has been extensively 
used to measure the biofield of human body [21]. Thus, human has the 
ability to harness the energy from environment or universe and can 
transmit into any living or nonliving object(s) around the Globe. The 
objects always receive the energy and responding into useful way that 
is called biofield energy and the process is known as biofield treatment. 
Mr. Trivedi’s unique biofield treatment (The Trivedi effect®) has been 
known to transform the structural, physical and thermal properties of 
several metals and ceramic in materials science [22-24], improved the 
overall productivity of crops [25,26], altered characteristics features of 
microbes [27-29] and improved growth and anatomical characteristics 
of medicinal plants [30,31].
Due to the clinical significance of this organism and literature on 
biofield treatment, the present work was undertaken to evaluate the 
impact of biofield treatment on C. braakii in relation to antimicrobials 
susceptibility and biotyping based on various biochemical characters 
followed by 16S rDNA sequencing analysis.
Materials and Methods
C. braakii, American Type Culture Collection (ATCC 43162) strain 
was procured from MicroBioLogics, Inc., USA and stored with proper 
storage conditions until further use. All the tested antimicrobials and 
biochemicals were procured from Sigma-Aldrich (MA, USA). The 
antimicrobial susceptibility, biochemical reactions and biotype number 
were estimated with the help of MicroScan Walk-Away® (Dade Behring 
Inc., West Sacramento, CA, USA) using Negative Breakpoint Combo 
30 (NBPC 30) panel with respect to control group (Gr.). The 16S rDNA 
sequencing study was carried out using ultrapure genomic DNA prep 
kit; Cat KT 83 (Bangalore Genei, India).
Experimental design
The impact of biofield treatment on tested bacterium C. braakii was 
evaluated in two groups-
Group I: ATCC strain was revived from lyophilized state and 
considered as control. No treatment was given and analyzed for 
antimicrobial sensitivity, biochemical reactions and biotype number as 
per the standard protocol. 
Group II: The lyophilized state of ATCC strain  was divided into 
two parts named as Gr. IIA and Gr. IIB. Both the groups of ATCC 
strain of C. braakii in lyophilized state were assigned to the Mr. Trivedi’s 
unique biofield treatment (first treatment). Gr. IIB sample was stored in 
lyophilized state for 159 days at -70ºC. Gr. IIB was further sub-divided 
in two separate parts named as Gr. IIB - Study I and Gr. IIB - Study II.
Group IIB - Study I 
After 159 days, antimicrobial sensitivity, MIC, biochemical 
reactions and biotyping were performed as per the standard protocol. 
Group IIB - Study II
The stored strain was revived from -70ºC and the revived culture 
was again provided to Mr. Trivedi’s biofield treatment (re-treatment) 
on day 159. After biofield retreatment, the sample was sub-cultured 
into three separate tubes on 3 different days (Day 0, Day 5 and Day 
10) and analysed keeping the main treated tube aside. Each sample was 
analyzed after 5 days of its sub-culturing. 
Biofield treatment strategy
The lyophilized (Gr. IIA) sample of C. braakii was subjected to Mr. 
Trivedi’s biofield treatment (first treatment) followed by retreatment 
after storing for 159 days in revived state (Gr. IIB, Study II). In details, 
the treatment groups in sealed pack were handed over to Mr. Trivedi for 
biofield treatment under laboratory conditions. Mr. Trivedi provided 
the treatment through his energy transmission process to the treated 
groups without touching the samples. After first treatment, the analysis 
of Gr. IIA lyophilized sample was done on day 10 for antimicrobial 
sensitivity along with minimum inhibitory concentration (MIC), 
biochemical reactions with biotype number and 16S rDNA analysis as 
per the standard protocol. While handing over these cultures to Mr. 
Trivedi for retreatment purposes, optimum precautions were taken to 
avoid contamination. 
Antimicrobial susceptibility test
Investigation of antimicrobial susceptibility of C. braakii was 
carried out with the help of automated instrument, MicroScan Walk-
Away® using NBPC 30 panel. The panel can be stored at 2 to 25ºC for 
analysis. The panel was allowed to equilibrate to room temperature 
prior to rehydration. All opened panels were used on the same day. 
The tests carried out on MicroScan were miniaturized of the broth 
dilution susceptibility test that has been dehydrated. Briefly, 0.1 mL 
of the standardized suspension of C. braakii was pipetted into 25 
mL of inoculum water using pluronic and inverted 8 to 10 times and 
inoculated, rehydrated, and then subjected to incubation for 16 hours at 
35°C. Rehydration and inoculation was performed using the RENOK® 
system with inoculators-D (B1013-4). 25 mL of standardized inoculum 
suspension was poured in to inoculum tray. The detailed experimental 
procedure and conditions were followed as per the manufacturer’s 
instructions. The antimicrobial susceptibility pattern (S: Susceptible, 
R: Resistant; and I: Intermediate) and MIC values were determined by 
observing the lowest antimicrobial concentration showing inhibition 
of growth [32].
Biochemical reaction studies
Biochemical reactions of C. braakii were determined using 
MicroScan Walk-Away®, system with NBPC 30 panel. Preparation of 
NBPC 30 panel, inoculum followed by dehydration and rehydration 
were performed in a similar way as mentioned in antimicrobial 
susceptibility assay for analysis of biochemical reactions followed by 
biotype number. The detailed experimental procedures and conditions 
were followed as per the manufacturer’s instructions [32].
Identification of organism by biotype number 
The biotype number of C. braakii was determined on MicroScan 
Walk-Away® processed panel data report with the help of biochemical 
reactions data [32]. 
Amplification and gene sequencing of 16S rDNA 
Genomic DNA was isolated from C. braakii cells (Gr. IIA, sample coded 
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as 4A) using genomic purification kit, according to the manufacturer 
instructions. 16S rDNA gene (~ 1.5 kb) fragment was amplified with the 
help of high-fidelity polymerase chain reaction (PCR) using universal 
primers; forward primer (5’-AGAGTTTGATCCTGGCTCAG-3’) and 
reverse primer (3’-ACGGTCATACCTTGTTACGACTT-5’). Amplified 
products were subjected to gel electrophoresis in 1.0% agarose gel, 
stained with ethidium bromide and visualized under UV light in a gel 
documentation unit (BioRad Laboratories, USA). The PCR amplified 
fragment was purified from the agarose gel using a DNA gel extraction 
kit. Sequencing of amplified product was done on commercial basis 
from Bangalore Genei, India. The 16S rDNA sequences obtained were 
aligned and compared with the sequences stored in GenBank database 
available from National Center for Biotechnology Information (NCBI) 
using the algorithm BLASTn program. Multiple sequence alignment/
phylogenetic tree were established using MEGA3.1 molecular software 
[33].
Results and Discussion
Antimicrobial susceptibility test
The results of C. braakii susceptibility pattern and MIC values of 
tested antimicrobials after biofield treatment are presented in Table 1 
and 2 respectively. The data were analyzed and compared with respect 
to control (Gr. I). Antimicrobial susceptibility assay was carried out 
using twenty-eight antimicrobials. Overall, the treated cells of C. 
braakii showed 39.29% alteration in antimicrobial sensitivity pattern 
as compared to control. The sensitivity pattern of tetracycline was 
changed from resistance (R) to susceptible (S) and simultaneously 
decreased MIC value by two folds (>8 to ≤ 4 µg/mL) in all the treated 
groups as compared to control (Gr. I). This improvement with 
respect to resistant pattern and MIC value could be due to biofield 
treatment. The effect was observed throughout the experiment. So, 
it may assume that the effect of biofield treatment was sustainable. 
Moreover, the antibiogram pattern of certain antimicrobials viz. 
aztreonam, cefotaxime, cefotetan, ceftazidime, ceftriaxone, cefuroxime, 
piperacillin/tazobactam, piperacillin and ticarcillin/k-clavulanate were 
changed from inducible β-lactamase (IB) to susceptible in lyophilized 
treated (first treatment) Gr. IIB, Study I on day 159 as well as in revived 
treated (second treatment) Gr. IIB, Study II on day 5 as compared 
to untreated sample (Gr. I). The microbe C. braakii has the ability to 
produce chromosomal β-lactamases. Thus, the overproduction of 
this enzymes lead to resistance in most of penem and cephems ring 
containing antimicrobials [34]. 
However, after biofield treatment the above mentioned nine 
antimicrobials were converted from IB to completely susceptible 
in lyophilized treated (first treatment) Gr. IIB, Study I on day 159 as 
well as in revived treated (second treatment) Gr. IIB, Study II on day 
5 as compared to control sample. However, the susceptibility pattern 
of these nine antimicrobials did not show any alteration in rest of 
the treated samples as compared to control. This alteration could be 
due to exertion of biofield energy to the treated samples at enzymatic 
S. No. Antimicrobial Gr. I (Control) Gr. IIA (Day 10) Gr. IIB (Study I; Day 159)
Gr. IIB (Study II; Day 159)
Day 5 Day 10 Day 15
1. Amikacin S S S S S S
2. Amoxicillin/k-clavulanate I I R R R R
3. Ampicillin/sulbactam I I I I I I
4. Ampicillin R R R R R R
5. Aztreonam IB IB S S IB IB
6. Cefazolin R R R R R R
7. Cefepime S S S S S S
8. Cefotaxime IB IB S S IB IB
9. Cefotetan IB IB S S IB IB
10. Cefoxitin R R R R R R
11. Ceftazidime IB IB S S IB IB
12. Ceftriaxone IB IB S S IB IB
13. Cefuroxime IB IB S S IB IB
14. Cephalothin R R R R R R
15. Chloramphenicol S S S S S S
16. Ciprofloxacin S S S S S S
17. Gatifloxacin S S S S S S
18. Gentamicin S S S S S S
19. Imipenem S S S S S S
20. Levofloxacin S S S S S S
21. Meropenem S S S S S S
22. Moxifloxacin S S S S S S
23. Piperacillin/tazobactam IB IB S S IB IB
24. Piperacillin IB IB S S IB IB
25. Tetracycline R S S S S S
26. Ticarcillin/k-clavulanate IB IB S S IB IB
27. Tobramycin S S S S S S
28. Trimethoprim/sulphamethoxazole S S S S S S
R: Resistant; S: Susceptible; I: Intermediate; IB: Inducible β-lactamase; Gr.: Group 
Table 1: Antibiogram of Citrobacter braakii: effect of biofield treatment on antimicrobial susceptibility. 
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levels and that may ceased or reduced formation of β-lactamase from 
those antimicrobials. As a consequence, these antimicrobials became 
completely susceptible to C. braakii even after two times biofield 
treatment as compared to control. Beside this, the MIC values of 
these nine antimicrobials did not show any alteration in all the treated 
samples while MIC value of cefuroxime was altered by two-fold (8 µg/
mL) in Gr IIA on day 10 as compared to the control. The antimicrobial 
sensitivity pattern and MIC value of amoxicillin/k-clavulanate were 
changed from I to R and (16/8 to >16/8 µg/mL) respectively in Gr. IIB, 
Study I on day 159 (first-time biofield treatment) and in Study II on day 
5, 10 and 15 after retreatment as compared to control. The MIC value 
of ESBL-a Scrn was slightly altered in Gr. II, Study II on day 10 after 
retreatment on day 159 as compared to the control. The MIC value of 
nitrofurantoin was decreased by two-fold (>64 to ≤ 32 µg/mL) in all 
the treated samples as compared to untreated sample (Table 2). Overall, 
15.63% MIC values of antimicrobials were altered out of thirty-two 
antimicrobials as compared to control. Rest of antimicrobials did not 
show any alteration in terms of antibiogram and MIC in all the treated 
samples as compared to the control.
Biochemical reactions studies
Study of biochemical reactions can be utilized to identify 
the enzymatic and metabolic characteristic feature of microbes. 
Microorganisms can be categorically differentiated based on their 
utilization of specific biochemicals as nutrients during the process of 
metabolism or enzymatic reactions. Data obtained from biochemical 
reactions studies for differentiation of C. braakii are illustrated in Table 
3. Biochemical indole (IND) was changed from negative (-) to positive 
(+) reaction in all the treated samples as compared to control (Gr. I). 
The key characteristics of C. braakii were positive reactions of ornithine 
decarboxylase (ORN) production and utilization of malonate (MAL) 
in control sample of C. braakii. The control data were supported with 
literature [35]. The biochemicals such as adonitol (ADO), colistin (CL4), 
esculin hydrolysis (ESC), nitrofurantoin (FD64), lysine (LYS), malonate 
(MAL), raffinose (RAF), sucrose (SUC), tryptophan deaminase (TDA), 
urea (URE), and Voges-Proskauer (VP) were changed from positive 
(+) to negative (-) reactions in all the treated samples as compared to 
control. Moreover, biochemical reaction of H2S was converted from 
positive (+) to negative reaction in Gr. IIB, study I on day 159 after first 
treatment and in Gr. IIB, study II on day 5 after retreatment with Mr. 
Trivedi’s biofield treatment as compared to control. Galactosidase was 
converted from positive (+) to negative (-) reaction in Gr. IIB, Study II 
on day 5 after retreated the sample on day 159 while remained same, 
i.e., positive (+) in all the others groups as compared to control. Overall, 
S. No. Antimicrobial Gr. I (Control) Gr. IIA (Day 10) Gr. IIB (Study I; Day 159)
Gr. IIB (Study II; Day 159)
Day 5 Day 10 Day 15
1. Amikacin ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16
2. Amoxicillin/k-clavulanate 16/8 16/8 >16/8 >16/8 >16/8 >16/8
3. Ampicillin/sulbactam 16/8 16/8 16/8 16/8 16/8 16/8
4. Ampicillin >16 >16 >16 >16 >16 >16
5. Aztreonam ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8
6. Cefazolin >16 >16 >16 >16 >16 >16
7. Cefepime ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8
8. Cefotaxime ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8
9. Cefotetan ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16
10. Cefoxitin >16 >16 >16 >16 >16 >16
11. Ceftazidime ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8
12. Ceftriaxone ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8
13. Cefuroxime ≤ 4 8 ≤ 4 ≤ 4 ≤ 4 ≤ 4
14. Cephalothin >16 >16 >16 >16 >16 >16
15. Chloramphenicol ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8 ≤ 8
16. Ciprofloxacin ≤ 1 ≤ 1 ≤ 1 ≤ 1 ≤ 1 ≤ 1
17. ESBL-a Scrn ≤ 4 ≤ 4 ≤ 4 ≤ 4 >4 ≤ 4
18. ESBL-b Scrn ≤ 1 >1 ≤ 1 ≤ 1 ≤ 1 ≤ 1
19. Gatifloxacin ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2
20. Gentamicin ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4
21. Imipenem ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4
22. Levofloxacin ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2
23. Meropenem ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4
24. Moxifloxacin ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2
25. Nitrofurantoin >64 ≤ 32 ≤ 32 ≤ 32 ≤ 32 ≤ 32
26. Norfloxacin ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4
27. Piperacillin/tazobactam ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16
28. Piperacillin ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16
29. Tetracycline >8 ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4
30 Ticarcillin/k-clavulanate ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16 ≤ 16
31. Tobramycin ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4 ≤ 4
32. Trimethoprim/sulphamethoxazole ≤ 2/38 ≤ 2/38 ≤ 2/38 ≤ 2/38 ≤ 2/38 ≤ 2/38
 MIC data are presented in µg/mL; Gr.: Group; ESBL a,b Scrn: Extended spectrum β-lactamase a and b screen
Table 2: Effect of biofield treatment on Citrobacter braakii to minimum inhibitory concentration (MIC) value of tested antimicrobials.
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biochemical reactions showed significant (42.42%) alteration in the 
treated groups with respect to control. Rest of the biochemicals did not 
show any alteration of biochemical reactions in all the treated groups as 
compared to control (Table 3).
Identification of organism by biotype number 
The species (C. braakii) were identified based on a variety of 
conventional biochemical characters and biotyping. Biotype number of 
particular organism was evaluated after interpreting the results of the 
biochemical reactions. The biotype number then led to the particular 
organism identification. In this experiment, biotyping was performed 
using an automated system, and results showed a significant change 
in biotype number (53131052) in Gr. IIA (on day 10) after first-time 
biofield treatment with identification of new species (Citrobacter 
freundii complex) as compared to control Gr. I (77365776; C. braakii). 
The term Citrobacter freundii complex have eight species out of 11 
identified genomospecies under the genus Citrobacter viz. Citrobacter 
jeundii, Citrobacter youngae, Citrobacter braakii, Citrobacter werkmanii, 
Citrobacter sedlakii and three unnamed Citrobacter species [2]. After 
that, these three genomospecies were named as Citrobacter rodentium, 
Citrobacter gillenii, and Citrobacter murliniae [35].
Moreover, the biotype numbers were also changed on day 159 
in Gr. IIB, Study I (53111052; Citrobacter amalonaticus) as well as in 
Gr. IIB, Study II after retreatment on day 5 (53111042; Citrobacter 
amalonaticus), day 10 (53131052; Citrobacter freundii complex), and 
on day 15 (53131052; Citrobacter freundii complex) as compared to 
the control (Table 4). These changes of biotype numbers may be due 
to alteration of several biochemical reactions under the influence of 
biofield treatment in the lyophilized state. Furthermore it is further 
assumed that the changes of biotype numbers could be due to first-time 
biofield treatment and sustained effects upto day 159.
16S rDNA genotyping
The bacteria that are poorly differentiated by conventional methods 
needs molecular analysis method like 16S rDNA sequence [36]. This 
molecular based technique is suitable tool for identification of most 
of bacteria on their genus and/or species level by comparison with 
databases in the public domain. Because, most of bacteria have small 
ribosomal subunit with their species-specific variability [37]. The 
16S rDNA sequence was determined in C. braakii on Gr. IIA sample. 
The alignment and comparison of the consensus gene sequences 
were performed with the sequences stored in GenBank database 
S. No. Code Biochemical Gr. I (Control) Gr. IIA(Day 10)
Gr. IIB (Study I;
Day 159)
Gr. IIB (Study II; Day 159)
Day 5 Day 10 Day 15
1. ACE Acetamide - - - - - -
2. ADO Adonitol + - - - - -
3. ARA Arabinose + + + + + +
4. ARG Arginine - - - - - -
5. CET Cetrimide - - - - - -
6. CF8 Cephalothin + + + + + +
7. CIT Citrate + + + + + +
8. CL4 Colistin + - - - - -
9. ESC Esculin hydrolysis + - - - - -
10. FD64 Nitrofurantoin + - - - - -
11. GLU Glucose + + + + + +
12. H2S Hydrogen sulfide + + - - + +
13. IND Indole - + + + + +
14. INO Inositol - - - - - -
15. K4 Kanamycin - - - - - -
16. LYS Lysine + - - - - -
17. MAL Malonate + - - - - -
18. MEL Melibiose + + + + + +
19. NIT Nitrate + + + + + +
20. OF/G Oxidation-fermentation/glucose + + + + + +
21. ONPG Galactosidase + + + - + +
22. ORN Ornithine + + + + + +
23. OXI Oxidase - - - - - -
24. P4 Penicillin + + + + + +
25. RAF Raffinose + - - - - -
26. RHA Rhamnose + + + + + +
27. SOR Sorbitol + + + + + +
28. SUC Sucrose + - - - - -
29. TAR Tartrate - - - - - -
30. TDA Tryptophan deaminase + - - - - -
31. TO4 Tobramycin - - - - - -
32. URE Urea + - - - - -
 33. VP Voges-Proskauer + - - - - -
 -, (negative); +, (positive); Gr.: Group; ONPG: Ortho-nitrophenyl-β-galactoside
Table 3: Effect of biofield treatment on Citrobacter braakii to the biochemical reactions pattern.
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Feature Gr. I (Control) Gr. IIA (Day 10) Gr. IIB (Study I; Day 159)
Gr. IIB (Study II; Day 159)
Day 5 Day 10 Day 15
Biotype 77365776 (Very rare biotype) 53131052 53111052 53111042 53131052 53131052
Organism Identification Citrobacter braakii Citrobacter freundii complex Citrobacter amalonaticus Citrobacter amalonaticus Citrobacter freundii complex Citrobacter freundii complex
Gr.: Group
Table 4: Effect of biofield treatment on Citrobacter braakii assessment of biotype number.
Alignment View AN Alignment Result Sequence Description
4A 0.96 Sample studied
DQ517285 0.95 Citrobacter freundii strain BRN1
DQ444289 0.98 Citrobacter freundii strain 6
AF025365 0.99 Citrobacter freundii
AY567708 0.98 Candidatus cuticobacterium kirbyi
DQ294285 0.97 Citrobacter freundii strain 7
AF025368 1.00 Citrobacter braakii
DQ294286 0.96 Citrobacter freundii strain 8
AB210978 0.98 Citrobacter freundii strain: SSCT56
AF025373 0.98 Citrobacter werkmanii
DQ517286 0.95 Citrobacter freundii strain BRN2
AN: GenBank Accession Number
Table 5: The closest sequences of Citrobacter braakii from sequence alignment using NCBI GenBank and ribosomal database project (RDP).
available from NCBI using the algorithm BLASTn program. Based on 
nucleotide homology and phylogenetic analysis the microbe (Sample 
4A) was detected as Citrobacter freundii (GenBank Accession Number: 
DQ517285) with 95% identity. The nearest homolog genus-species 
of C. braakii was found to be Citrobacter werkmanii (Accession No. 
AF025373). Some other close homologs of C. braakii were found 
from the alignment results as shown in Table 5. The distance matrix 
based on nucleotide sequence homology data are presented in Table 
6. Phylogenetic tree was established using BLAST-Webpage (NCBI). 
According to Table 6, ten different related bacterial species of C. 
braakii were selected as Operational Taxonomic Units (OTUs) in 
order to investigate the phylogenetic relationship of C. braakii. There 
were 1498 base nucleotides of 16S rDNA gene sequences, which were 
analyzed and multiple alignments were constructed using ClustalW in 
MEGA3.1. The numbers of base substitutions per site from pairwise 
distance analysis between sequences are shown in Table 5. All results 
were based on the pairwise analysis of 11 sequences. According to the 
data in Table 6, the lowest value of genetic distance from C. freundii 
strain BRN1 was 0.004 base substitutions per site. This value is due to 
the distance between C. braakii and C. freundii. All pairwise distance 
analysis was carried out using the p-distance method in MEGA3.1. The 
proportion of remarked distance, sometimes also called p-distance and 
showed as the number of nucleotide distances site. Values in Table 5 are 
programmed into Figure 1 with optimal bootstrap consensus tree. In 
the phylogram, there were eleven OTUs. The results suggested that C. 
braakii was closely related to the C. freundii with 95% similarity and the 
lowest genetic distance 0.004 base substitutions per site. 
Biofield treatment might be responsible for alteration in 
microorganism at genetic level and/or enzymatic level, which may act 
on receptor protein. While altering receptor protein, ligand-receptor/
Distance Matrix
AN 1 2 3 4 5 6 7 8 9 10 11
AF025365 1 — 0.997 0.999 0.995 0.998 0.995 0.991 0.995 0.994 0.996 0.994
AF025368 2 0.003 — 0.996 0.994 0.995 0.992 0.989 0.994 0.993 0.995 0.991
DQ444289 3 0.001 0.004 — 0.995 0.998 0.993 0.991 0.994 0.993 0.996 0.994
DQ294286 4 0.005 0.006 0.005 — 0.995 0.990 0.988 0.993 0.989 0.995 0.991
AY567708 5 0.002 0.005 0.002 0.005 — 0.993 0.991 0.993 0.992 0.995 0.993
AB210978 6 0.005 0.008 0.007 0.010 0.007 — 0.986 0.990 0.988 0.991 0.988
DQ517285 7 0.009 0.011 0.009 0.012 0.009 0.014 — 0.989 0.991 0.989 0.996
AF025373 8 0.005 0.006 0.006 0.007 0.007 0.010 0.011 — 0.992 0.994 0.989
DQ517286 9 0.006 0.007 0.007 0.011 0.008 0.012 0.009 0.008 — 0.990 0.988
DQ294285 10 0.004 0.005 0.004 0.005 0.005 0.009 0.011 0.006 0.010 — 0.991
4A 11 0.006 0.009 0.006 0.009 0.007 0.012 0.004 0.011 0.012 0.009 —
AN: GenBank Accession Number
Table 6: Distance matrix of Citrobacter braakii sample based on nucleotide sequence homology (using kimura-2 parameter).
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protein interactions may alter that could lead to show different phenotypic 
characteristics [38]. Biofield treatment might induce significant changes 
in lyophilized strain of C. braakii and alter antimicrobials susceptibility 
pattern, MIC values, biochemical reactions, which ultimately change 
the biotype number of microorganism. As a result, the microbe that 
was intermediate/resistant to a particular antimicrobial in control 
sample now converted into susceptible in treated cells of C. braakii 
predominately after biofield treatment. In this experiment, the main 
objective was to see the impact of Mr. Trivedi’s biofield treatment on an 
opportunistic hospital acquired pathogen of C. braakii in in vitro. Based 
on above findings the antimicrobials those are resistance/inducible 
β-lactamase producing now converted into absolutely susceptible 
after biofield treatment. So far our group had been published many 
research articles regrading short-term effects on biofield treatment on 
ATCC and multidrug resistant (MDR) strains [27-29]. This is the first 
report exploring the sustained effects of Trivedi’s biofield treatment on 
microorganism i.e. C. braakii. Based on these results, it is expected that 
biofield treatment has the scope to be an alternative approach than the 
existing antimicrobial therapy in near future.
Conclusion
In conclusion, the antimicrobial susceptibility pattern and MIC 
values showed 39.29% and 15.63% alteration, respectively of tested 
antimicrobials as compared to the control strain of C. braakii. The 
biochemical reactions pattern showed significant (42.42%) alteration 
as compared to control. Moreover, the biotype numbers of biofield 
treated strain of C. braakii were also changed in all the treated groups 
as compared to control. Based on changed biotype numbers after 
biofield treatment, new species were identified as Citrobacter freundii 
complex and Citrobacter amalonaticus in treated cells with respect to 
control Gr. I (77365776; C. braakii). Thus, Mr. Trivedi’s unique biofield 
treatment could be applied as an alternative therapeutic approach 
against antimicrobials resistance. Molecular based 16S rDNA analysis 
showed that the treated lyophilized sample in this experiment was C. 
braakii and was converted to Citrobacter freundii (GenBank Accession 
Number: DQ517285) after biofield treatment. However, the nearest 
homolog genus-species was found to be Citrobacter werkmanii 
(Accession No. AF025373). Based on these results, it seems that biofield 
treatment could be used as alternate of existing drug therapy in future.
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